Xcout Intel
Vaxdyn
Vaxdyn is a Seville-based biotechnology spin-off founded in 2011 that develops safe and effective multi-pathogen vaccines to prevent dangerous bacterial infections.
Subscribe to see Vaxdyn’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Vaxdyn at a glance
Vaxdyn is a biotechnology company headquartered in Spain. It has raised at least $25.1M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $12.1M in September 2026. Xcout tracks 4 named people at Vaxdyn, including Juanjo Infante (CEO and Chairman of the Board).
Vaxdyn leadership
- Juanjo InfanteCEO and Chairman of the Board
- Cristina ReinaDirector
- Francisco LeonDirector, Pharma Expert
- Ricardo Perdigão HenriquesDirector
Vaxdyn funding rounds
At least $25.1M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $12.1M | 5 named | |
| Series A | $13M | 6 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Vaxdyn news
Investors
Vaxdyn competitors
A few of Vaxdyn's closest competitors — see the full list of competitors and alternatives →
BioVersys AG is an award-winning, privately-owned Swiss pharmaceutical and biotech company headquartered in Basel, Switzerland, focused on the research and development of antibacterial treatments for drug-resistant bacterial infections.
LimmaTech Biologics is a Swiss clinical-stage biotechnology company developing vaccines against bacterial infections, including drug-resistant pathogens. Its work includes conjugate vaccine candidates for Shigella and other diseases, serving pharmaceutical partners and ultimately patients at risk of serious bacterial infections.
Alopexx, Inc. is a U.S. biotechnology company developing broad-spectrum anti-infective vaccines and antibody-based therapies. Its programs target PNAG, a surface polysaccharide found on many bacterial and fungal pathogens, for potential treatment or prevention of serious infections.
MalarVx, Inc. is a clinical-stage biopharmaceutical vaccine company located in Seattle, Washington, founded to develop innovative vaccines addressing global infectious diseases.
Omnix Medical is a biopharmaceutical company that develops novel antibiotic agents and antimicrobial peptides to treat infections caused by drug-resistant bacteria. The company focuses on creating first-in-its-class anti-infective therapeutics, such as its lead compound OMN6, to target life-threatening bacterial strains.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Get Vaxdyn's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Vaxdyn in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access